A nurse is reviewing the ultrasound report of a client who is at 31 weeks of gestation and has pre-term labor.

Which of the following findings indicates oligohydramnios?

Magnesium sulfate is a drug that is used to prevent seizures associated with pre-eclampsia and to stop preterm labor.However, it can also cause adverse effects such as respiratory depression, which is a condition where the breathing rate becomes too slow and shallow.

Respiratory depression can be life-threatening for both the mother and the baby, so the nurse should monitor the client’s respiratory rate and oxygen saturation closely.

Choice A is wrong because magnesium sulfate can cause hypotension, not hypertension.Hypotension is low blood pressure, which can lead to dizziness, fainting, and shock.

Choice B is wrong because magnesium sulfate can cause hyporeflexia, not hyperreflexia.Hyporeflexia is a reduced or absent reflex response, which can indicate magnesium toxicity.

The nurse should check the client’s deep tendon reflexes regularly and stop the infusion if they are absent.

Choice D is wrong because magnesium sulfate can cause bradycardia, not tachycardia.

Bradycardia is a slow heart rate, which can reduce the blood flow to vital organs.

Magnesium sulfate is a tocolytic drug that inhibits uterine activity and relaxes smooth muscles.The goal of magnesium sulfate therapy for a client who is in pre-term labor is to stop or reduce the frequency and intensity of contractions.

Choice B is wrong because the client’s blood pressure decreases to within normal limits.

Magnesium sulfate is not an antihypertensive drug and does not lower blood pressure.It is used to prevent seizures in clients with preeclampsia or eclampsia.

Choice C is wrong because the client’s deep tendon reflexes are 2+.

This is a normal finding and does not indicate the effectiveness of magnesium sulfate therapy.A decrease or loss of deep tendon reflexes may indicate magnesium toxicity, which is a serious complication that requires immediate intervention.

Choice D is wrong because the client’s urine output increases to more than 30 mL/hr.

This is also a normal finding and does not indicate the effectiveness of magnesium sulfate therapy.A decrease in urine output may indicate renal impairment or magnesium toxicity, which are both adverse effects of the drug.

The normal range for serum magnesium level is 1.5 to 2.5 mEq/L or 1.8 to 3 mg/dL.The therapeutic range for magnesium sulfate management is 5 to 8 mg/dL.